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ABSTRACT
The start of the menopausal transition involves the introduction of various somatic, urogenital,
and psychological symptoms; of the symptoms, irritability is one of the main complaints reported
by women. The use of bioidentical hormone replacement therapy has become more prevalent in
society, specifically treating the somatic and urogenital symptoms of the menopausal transition.
This study aims to determine the effects of bioidentical hormone replacement therapy (BHRT) on
irritability in menopausal women. To test the hypotheses, an online survey was distributed to
women via social media and word-of-mouth. Participants were asked to respond to various
questions, which were then analyzed based on BHRT use. An independent samples t-test was
used to analyze the data. The results exemplified no significant relationship between BHRT and
irritability; using BHRT does not significantly reduce irritability scores.
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INTRODUCTION
The Menopausal Transition
In the United States, there are an estimated 57 million women at least 45 years of age. Of
these women, approximately 6,000 reach menopause each day (Whiteley et al., 2013).
Menopause is defined as the complete cessation of menstruation for 12 consecutive months and
can occur naturally, surgically, or in response to alternative medical conditions. A wide range of
symptoms characterize the menopausal transition; women may experience adverse vasomotor
(hot flashes, cold sweats, and night sweats), urogenital (vaginal dryness, frequency, and urgency
of urination), and psychological symptoms (irritability, mood changes, anxiety, and depression)
(Terauchi et al., 2013).
The menopausal transition occurs in three stages: perimenopause, menopause, and
postmenopause. During perimenopause, approximately eight years before menopause, a
woman’s hormones are highly acyclic. It is during this phase of the menopausal transition that
many symptoms arise. The end of perimenopause, and the start of menopause, is signified by the
cessation of menstrual periods for 12 consecutive months. In menopause, a women’s ovaries halt
the release of eggs and estrogen production; it is in menopause that most women experience mild
to severe symptoms. With the complete cessation of menstrual periods, a woman will live the
remainder of their life in postmenopause. In postmenopause, menopausal symptoms may begin
to ease; however, there is also an increased risk of health conditions (i.e., osteoporosis and heart
disease).
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Irritability
Snaith and Taylor defined irritability as “a feeling state characterized by reduced control
over temper which usually results in irascible verbal or behavioral outbursts, although the mood
may be present without observed manifestation” (1985, p. 128). Irritability is one of the chief
complaints of the menopausal transition; however, research is still minimal on the topic.
Researchers also argue that irritability occurs because of the domino effect—vasomotor
symptoms cause irritability. There are also alternative causes of irritability, including various
mental health disorders, chronic medical conditions, and substance withdrawal. In a study
prepared to investigate irritability in menopause (Spyropoulou et al., 2009), researchers
identified outward-directed and inward-directed irritability in menopausal women to be related to
pre-existing chronic disease (hypertension, cardiac disease, diabetes mellitus, or thyroid disease).
Results also exemplified a link between outward irritability and follicle-stimulating hormone
(FSH) and luteinizing hormone (LH) levels—with effect sizes 22.2% and 37.0%; elevated FSH
and LH levels are indicative of the later years of the menopausal transition.
A study (Mauas et al., 2014) performed to investigate self-criticism and whether it
moderates the effects of irritability on depressive symptoms experienced during the menopausal
transition exemplified the prevalence of irritability in menopause. Furthermore, the data
indicated that higher irritability levels were more prevalent in the early phases of the menopausal
transitions than pre-and postmenopausal women. Moreover, the data exemplified two trends
regarding irritability and depressive symptoms: depressive symptoms remain static throughout
the menopausal transition, whereas irritability appears to be higher in the earlier stages and
improves over time. These findings contribute to the idea that irritability may have hormonal
implications and may not be linked to solely the symptoms of depression.
2

Hormone Replacement Therapy
To mitigate the symptomology of menopause, women sought alternative treatments, one
of which was hormone replacement therapy (HRT). Synthetic hormones are frequently derived
from animals and include conjugated equine estrogens (CEE), medroxyprogesterone acetate
(MPA), and other synthetic progestins (Holtorf, 2009). In a study examining the annual trends of
HRT in the United States, between the years 1995 and 2000, nearly 15 million women were
prescribed hormone therapy annually (Hersh et al., 2004). However, these numbers drastically
declined in 2002, following the Women’s Health Initiative (WHI) trials, which examined the
risks and benefits of HRT for chronic disease prevention. The study results suggested that the
overall dangers of HRT outweighed the benefits, including an increased risk in both invasive
breast cancer and coronary heart disease (CHD) (Manson et al., 2013). As a result of the WHI
trials, the focus on treatment for menopausal symptoms turned towards bioidentical hormone
replacement therapy, which appeared to be a safer alternative than traditional hormonal
replacement therapy.

Bioidentical Hormone Replacement Therapy
Unlike traditional synthetic hormones, “bioidentical hormones are generally derived from
plant extracts but are chemically modified in a laboratory to be structurally indistinguishable
from human endogenous hormones” (Fishman et al., 2015). Prescribers of BHRT often operate
in conjunction with compounding pharmacies. Compounding pharmacies offer individualized
hormone combinations and dosages and various administration modes that are not provided at
standard pharmacies. Like hormone replacement therapy, bioidentical hormone replacement
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therapy has also been identified as a treatment for the adverse physical and psychological
symptoms of the menopausal transition. In a meta-analysis (Whedon et al., 2017) completed to
investigate the effects of bioidentical estrogen on menopausal depressive symptoms, it was
inferred that although the use of bioidentical estrogen resulted in improvements in vasomotor
symptoms (i.e., hot flashes, night sweats, cold sweats), the results were not significant enough to
identify changes in depressive symptoms.
In an observational cohort study (Ruiz et al., 2011) conducted to identify the
effectiveness of compounded bioidentical hormone replacement therapy, researchers observed
women using specified BHRT dosages and regimens between 2003 and 2010. The results
exemplified significant reductions in moderate to severe mood symptoms within 3 to 6 months.
The results also exemplified an overall decrease in emotional lability, irritability, and anxiety.
Numerous physicians suggest that the bioidentical route is safer and individualized to each
patient rather than a ‘one size fits all’ approach.

Expanding the Literature
Although there has been research on the menopausal transition, research on the use of
BHRT to treat the psychological symptoms is still limited. This study will contribute to the
literature by producing a better understanding of the use of BHRT to treat menopausal
symptoms, specifically irritability. This study will also provide research on the correlation
between inward/outward-directed irritability and anxiety and depression. It is already understood
that BHRT can effectively treat the physical symptoms, and therefore, it is possible that using
bioidentical hormones may lessen the psychological effects.
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This study's primary purpose is to investigate the effects of bioidentical hormone
replacement therapy on irritability in menopausal women. The impact of this type of treatment
on symptoms will be assessed through a questionnaire focused on irritability; scoring will reveal
any possible correlations between irritability and menopause. Based on prior research, it is likely
that BHRT will positively affect the physical symptoms of menopause. It is also expected that
the most significant irritability scores will be seen in perimenopause; this is due primarily to the
acyclicity of a woman’s hormones during this phase. Furthermore, it is possible for participants
who are not using hormone therapy to report the highest scores on the outward-directed
irritability subscale; this prediction is based on Spyropoulou’s research, which indicated a
positive correlation between FSH and LH levels and outward-directed irritability scores.
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METHOD
Participants
Women ages 30-89 who are currently in menopausal transition were recruited through social
media and word-of-mouth. The initial age range selected was 18-89; however, because this study
focused on the latter of the menopausal transition (perimenopause, menopause, and
postmenopause), the age range was refined.

Materials
Irritability, Depression, and Anxiety (IDA) Scale: A validated scale that measures
participants' current feelings through four subscales: anxiety, depression, inward-directed
irritability, and outward-directed irritability. Participants were asked to read the questions (18)
and respond by selecting one of four responses. The reliability coefficients for the depression
scale ranged between .72 and .81; for the anxiety scale, they ranged between .74 and .87; the
outward-directed irritability scale ranged between .77 and .88, and the inward-directed irritability
scale ranged between .70 and .93 (Snaith et al., 1978, p. 167). See Appendix A.
Menopause Health Questionnaire: A modified questionnaire focusing on participant’s
gynecological history, menopausal history, and hormone therapy use. See Appendix B.
Menopause Rating Scale (MRS): A self-rating scale designed to measure the severity of
the somatic, psychological, and urogenital symptoms of menopause. See Appendix C.
Demographics Scale: A questionnaire regarding basic background information.
Participants will be asked their age, gender, ethnicity, current location, education, marital status,
and employment. See Appendix D.
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Additional Questions: Additional questions will be asked for use in post hoc analyses.
These questions regard participant physical health conditions, mental health conditions and
treatment, caffeine intake, current stressors, and personal habits. These questions will be
incorporated into the modified Menopause Health Questionnaire. See Appendix B.

Design and Procedure
To assess whether BHRT influences irritability in menopausal women, two groups were
evaluated: women using BHRT and women who do not use any HRT form. Before beginning
the Qualtrics survey, participants were presented with the informed consent form, which
provided information on the study and contact information if any questions arose. After
providing consent, participants were presented with the Menopause Rating Scale (MRS), the
menopause health questionnaire and additional questions, the Irritability, Depression, and
Anxiety Scale (IDA), and Demographics Scale. All surveys were completed online
anonymously.
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RESULTS
Data screening procedures were implemented to ensure reliable data. Participants who did not
complete the Qualtrics survey were not included in the data. Due to a limited number of
participants, anyone who had not been using BHRT for a year or more was removed from the
data. Additionally, only Caucasian participants were included due to a lack of diversity in the
data.
General Demographics
There were 79 eligible participants whose ages ranged between 37 and 80 (M = 57.34).
Of the participants, 7.6% were premenopausal, 13.9% were in perimenopause, 20.3% were in
menopause, and 58.2% were in postmenopause. 73.4% of participants reported not using BHRT,
while 26.6% reported currently using BHRT.

Analyzing the Relationship Between BHRT and Outward and Inward Directed Irritability
An independent samples t-test was performed between participants using BHRT or not
and inward and outward directed irritability—2 subscales of the Irritability, Depression, and
Anxiety Scale. For outward-directed irritability there was not a significant difference in the
scores for those who use BHRT (M=2.71, SD=1.62) and those who do not use BHRT (M = 2.81,
SD = 1.59; t(77) = -.236, p = .814).
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Figure 1: Mean Scores for Outward-Directed Irritability

For inward-directed irritability there was not a significant difference in scores between those
using BHRT (M =1.52, SD = 2.04) and those who do not use BHRT (M = 1.59, SD = 1.85; t(77)
= -1.29, p = .898).
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Figure 2: Mean Scores for Inward-Directed Irritability

Analyzing the Relationship Between BHRT and the Menopause Rating Scale Symptoms
An independent samples t-test was used to analyze the effects of BHRT on the symptoms
presented in the Menopause Rating Scale—specifically somatic and urogenital symptoms. For
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the somatic symptoms there was not a significant difference in the scores for those who use
BHRT (M = 4.00, SD = 2.95) and those who do not use BHRT (M = 4.48, SD = 2.77; t(77) = .673, p = .503).
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Figure 3: Mean Scores for Somatic Symptoms

For urogenital symptoms there were no significant differences in the scores of those who use
BHRT (M = 2.57, SD = 1.96) and those who do not use BHRT (M = 3.22, SD = 2.44; t(77) = .1.10, p = .273).
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Figure 4: Mean Scores for Urogenital Symptoms
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Analyzing the Differences Between BHRT and non-BHRT Groups
An independent samples t-test was also utilized to assess the similarities and differences
between the BHRT and non-BHRT groups to ensure equal comparison. The first dependent
variable tested was age; results exemplified no significant difference in age between the BHRT
group (M = 55.24, SD = 8.87) and the non-BHRT group (M = 58.10, SD = 8.02; t(77) = -1.36, p
= .177). The second dependent variable was stressors (elaborate on demographic question); data
illustrated no significant difference in stressors between the BHRT group (M = 1.50, SD = .607)
and the non-BHRT group (M = 1.66, SD = .690; t(77) = -.893, p = .375).

11

DISCUSSION
The hypothesis that women using bioidentical hormone replacement therapy would report
lower scores on inward and outward-directed irritability than those who do not use bioidentical
hormone replacement therapy was tested. The hypothesis that women using BHRT would score
lower on the physical subscales—urogenital and somatic—of the Menopause Rating Scale than
those not using BHRT was also tested. The results indicated that there was no significant
relationship between the use of BHRT and low irritability for women in the menopausal
transition. There was also no significant difference in scores for somatic and urogenital
symptoms between groups. While the results were not statistically significant, it is evident that
the BHRT and non-BHRT groups were not fundamentally dissimilar when comparing groups.
The findings were inconsistent with previous research on the effectiveness of bioidentical
hormone replacement therapy, which exemplified improvement of the physical (Whedon et al.,
2017) and psychological (Ruiz et al., 2011) symptoms experienced during the menopausal
transition. These results may vary from prior research due to differences in the construct of the
study. In both Whedon and Ruiz’s studies, the test scales used focused more heavily on
depression rather than irritability; these questionnaires did not include subscales of irritability
specifically similar to the Irritability, Depression, and Anxiety Scale used in this study.
It is also important to note the limitations of this study, the first being insufficient sample
size. There are nearly 6,000 women in the United States reaching the menopausal transition each
day, and therefore, larger sample size is needed to represent better the population being
researched. A larger sample in this study may have increased power leading to significant results.
Additionally, a more diversified sample size would also provide more information across
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cultures as the menopausal transition is experienced differently. A second limitation encountered
during this study was the lack of previous research on the topics of irritability in menopause and
the use of BHRT to treat the psychological symptoms of the menopausal transition. The lack of
prior research on these topics encouraged an alternative research methodology—exploratory
research—for this study.
Going forward, it is necessary that more research is done on women and their experiences
during the menopausal transition because this s a critical period of time in a woman’s life. More
research must be done to better understand irritability as a mood state in women, specifically
during the menopausal transition. Further studies should focus on adapting a reliable, irritabilityspecific scale for women.
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